Identifying Common Genetic Risk Factors of Diabetic Neuropathies
暂无分享,去创建一个
Herbert F. Jelinek | Ahsan H. Khandoker | Kinda Khalaf | Habiba Alsafar | A. Khandoker | H. Jelinek | Habiba S. Alsafar | K. Khalaf | Sungmun Lee | Sungmun Lee | Ini-Isabée Witzel | Ini-Isabée Witzel
[1] P. Oates. Aldose reductase inhibitors and diabetic kidney disease. , 2010, Current opinion in investigational drugs.
[2] C. Zoccali,et al. Autonomic function in uremic patients treated by hemodialysis or CAPD and in transplant patients. , 1986, Clinical nephrology.
[3] Jørgen K. Kanters,et al. Cardiac repolarization during hypoglycaemia and hypoxaemia in healthy males: impact of renin-angiotensin system activity. , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[4] V. Lyssenko,et al. Genetics of diabetes complications , 2014, Mammalian Genome.
[5] A. Vinik,et al. Diabetic Cardiovascular Autonomic Neuropathy , 2007, Circulation.
[6] R. Vasan,et al. Identification of cis- and trans-Acting Genetic Variants Explaining Up to Half the Variation in Circulating Vascular Endothelial Growth Factor Levels , 2011, Circulation research.
[7] Tian-biao Zhou,et al. Meta‐analysis of the relationship between ACE I/D gene polymorphism and end‐stage renal disease in patients with diabetic nephropathy , 2012, Nephrology.
[8] T. Hansen,et al. What Is the Contribution of Two Genetic Variants Regulating VEGF Levels to Type 2 Diabetes Risk and to Microvascular Complications? , 2013, PloS one.
[9] Role of interleukin-6 levels in cardiovascular autonomic dysfunction in type 2 diabetic patients , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[10] T. Hayashi,et al. Genetic variations associated with diabetic nephropathy and type II diabetes in a Japanese population. , 2007, Kidney international. Supplement.
[11] J. Jonas,et al. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration. , 2012, Ophthalmology.
[12] Jean Tichet,et al. Gene polymorphisms of the renin‐angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study , 1998, Journal of hypertension.
[13] G. Mamikunian,et al. Cardiac Autonomic Imbalance in Newly Diagnosed and Established Diabetes Is Associated with Markers of Adipose Tissue Inflammation , 2011, Experimental diabetes research.
[14] E. Jaimes,et al. Role of L-arginine in the pathogenesis and treatment of renal disease. , 2004, The Journal of nutrition.
[15] E. Maltezos,et al. An insertion/deletion polymorphism in the alpha2B adrenoceptor gene is associated with peripheral neuropathy in patients with type 2 diabetes mellitus. , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[16] I. Rosenberg,et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. , 1996, Circulation.
[17] N. Karakuş,et al. Association of MTHFR gene C677T mutation with diabetic peripheral neuropathy and diabetic retinopathy , 2013, Molecular vision.
[18] Lequn Li,et al. Methylenetetrahydrofolate Reductase Gene Polymorphism and Risk of Type 2 Diabetes Mellitus , 2013, PloS one.
[19] Dyah Purnamasari,et al. ACE gene polymorphism and atherosclerotic lesion of carotid artery among offsprings of type 2 diabetes mellitus. , 2012, Acta medica Indonesiana.
[20] P. Oates. Aldose reductase, still a compelling target for diabetic neuropathy. , 2008, Current drug targets.
[21] A. Chakravarti,et al. Associations Between Hypertension and Genes in the Renin-Angiotensin System , 2003, Hypertension.
[22] C. Bănescu,et al. Vascular Endothelial Growth Factor Insertion/Deletion gene polymorphism in patients with type 2 diabetes and diabetic peripheral polyneuropathy , 2014 .
[23] N. Palmer,et al. Diabetic nephropathy: FRMD3 in diabetic nephropathy—guilt by association , 2013, Nature Reviews Nephrology.
[24] H. Hammes,et al. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. , 2005, Diabetes.
[25] I. G. Fantus,et al. High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor. , 2002, American journal of physiology. Endocrinology and metabolism.
[26] D. Yarnitsky,et al. Paradoxical heat sensation in uremic polyneuropathy , 1995, Muscle & nerve.
[27] M. Shen,et al. Hyperhomocysteinemia, deep vein thrombosis and vitamin B12 deficiency in a metformin-treated diabetic patient. , 2007, Journal of the Formosan Medical Association = Taiwan yi zhi.
[28] Yusuke Nakamura,et al. Replication Study for the Association Between Four Loci Identified by a Genome-Wide Association Study on European American Subjects With Type 1 Diabetes and Susceptibility to Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes , 2010, Diabetes.
[29] S. Chan,et al. Null association between ACE gene I/D polymorphism and diabetic nephropathy among multiethnic Malaysian subjects , 2010, Indian journal of human genetics.
[30] H. Rakugi,et al. ACE Insertion/Deletion Polymorphism and Cardiovascular Effect of Hypercholesterolemia. , 2015, Journal of atherosclerosis and thrombosis.
[31] G. Dibona,et al. Neural control of renal function. , 2011, Comprehensive Physiology.
[32] T. Nakagawa. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. , 2007, American journal of physiology. Renal physiology.
[33] Archana Singh,et al. Role of the renin angiotensin system in diabetic nephropathy. , 2010, World journal of diabetes.
[34] M. Mattson,et al. Toll-like receptors 2 and 4 modulate autonomic control of heart rate and energy metabolism , 2014, Brain, Behavior, and Immunity.
[35] Gary C. Brown,et al. ASSOCIATION BETWEEN HIGH-RISK DISEASE LOCI AND RESPONSE TO ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION , 2012, Retina.
[36] P. Osaadon,et al. A review of anti-VEGF agents for proliferative diabetic retinopathy , 2014, Eye.
[37] H. Ross,et al. Nitric oxide and cardiac autonomic control in humans. , 2000, Hypertension.
[38] S. Shaughnessy,et al. Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.
[39] R. Berg,et al. A Systematic Review and Meta-analysis , 2010 .
[40] E. Feldman,et al. Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy , 2013, Experimental Neurology.
[41] K. Kostev,et al. Amputation rate and risk factors in type 2 patients with diabetic foot syndrome under real-life conditions in Germany. , 2012, Primary care diabetes.
[42] Melissa J. Morine,et al. Next-generation sequencing identifies TGF-β1-associated gene expression profiles in renal epithelial cells reiterated in human diabetic nephropathy. , 2012, Biochimica et biophysica acta.
[43] A. Levy,et al. The genetics of vascular complications in diabetes mellitus. , 2010, Cardiology clinics.
[44] O. Hill. A Twin Study , 1968, British Journal of Psychiatry.
[45] M. Cooper,et al. Mechanisms of diabetic complications. , 2013, Physiological reviews.
[46] A. D. den Hollander,et al. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration. , 2014, Ophthalmology.
[47] P. Binkley,et al. A polymorphism of the endothelial nitric oxide synthase promoter is associated with an increase in autonomic imbalance in patients with congestive heart failure. , 2005, American heart journal.
[48] D. Margolis,et al. Diabetes, lower extremity amputation, loss of protective sensation, and neuronal nitric oxide synthase associated protein in the Chronic Renal Insufficiency Cohort study , 2013, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[49] C. Winkler,et al. Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[50] Influence of apolipoprotein E genotype on the response to caloric restriction in type 2 diabetic patients with hyperlipidaemia , 2003, Diabetes, obesity & metabolism.
[51] S. Massry. Is parathyroid hormone a uremic toxin? , 1977, Nephron.
[52] S. Grant,et al. Genetic Susceptibility to Type 2 Diabetes and Obesity: Follow-Up of Findings from Genome-Wide Association Studies , 2014, International journal of endocrinology.
[53] U. Förstermann,et al. Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace , 2006, Circulation.
[54] A. Settin,et al. Association of ACE and MTHFR genetic polymorphisms with type 2 diabetes mellitus: Susceptibility and complications , 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[55] C. Guja,et al. Identification of gene variants in NOS3, ET-1 and RAS that confer risk and protection against microangiopathy in type 2 diabetic obese subjects. , 2011, Biochemical and biophysical research communications.
[56] E. Feldman,et al. Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy , 2009, Diabetes.
[57] N. Yorioka,et al. T-786→C Polymorphism of the Endothelial Nitric Oxide Synthase Gene Influences the Progression of Renal Disease , 2002, Nephron.
[58] Apolipoprotein E gene polymorphism and its effect on anthropometric measures in normoglycemic subjects and type 2 diabetes , 2012, Journal of Diabetes & Metabolic Disorders.
[59] G. Said,et al. Diabetic neuropathy—a review , 2007, Nature Clinical Practice Neurology.
[60] O. Melemedjian,et al. Proteomic and functional annotation analysis of injured peripheral nerves reveals ApoE as a protein upregulated by injury that is modulated by metformin treatment , 2013, Molecular pain.
[61] F. Wang,et al. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. , 2015, The lancet. Diabetes & endocrinology.
[62] D Crisan,et al. Angiotensin I-Converting Enzyme Genotype and Disease Associations , 2000 .
[63] J. Felício,et al. Autonomic neuropathy tests correlate with left ventricular mass and cardiac diastolic function in normotensive patients with type 2 diabetes mellitus and without left ventricular hypertrophy. , 2010, Experimental and clinical cardiology.
[64] M. Itoh,et al. Hypovitaminosis D in type 2 diabetes mellitus: Association with microvascular complications and type of treatment. , 2006, Endocrine journal.
[65] D. Tárnoki,et al. Effects of genetic vs. environmental factors on cardiovascular autonomic function: a twin study , 2011, Diabetic medicine : a journal of the British Diabetic Association.
[66] S. Kaya,et al. High Association of IL-4 Gene Intron 3 VNTR Polymorphism with Diabetic Peripheral Neuropathy , 2013, Journal of Molecular Neuroscience.
[67] Y. Fujio,et al. MTHFR gene polymorphism and diabetic retinopathy. , 2006, Current diabetes reviews.
[68] D. D. de Luis,et al. Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2. , 2004, Journal of diabetes and its complications.
[69] Z. Fang,et al. Human genetics of diabetic vascular complications , 2013, Journal of Genetics.
[70] P. Seshiah,et al. Angiotensin II Stimulation of NAD(P)H Oxidase Activity: Upstream Mediators , 2002, Circulation research.
[71] W. So,et al. Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 −455T>C polymorphisms on the susceptibility to diabetic nephropathy , 2006, Clinical genetics.
[72] Michael J. González,et al. Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. , 2011, Current clinical pharmacology.
[73] J. Blackwell,et al. A Genome‐Wide Search for Type 2 Diabetes Susceptibility Genes in an Extended Arab Family , 2013, Annals of human genetics.
[74] A. Hishida,et al. Cardiac Autonomic Neuropathy in Patients with Chronic Renal Failure on Hemodialysis , 2000, Nephron.
[75] S. Araki. APOE polymorphism and diabetic nephropathy , 2014, Clinical and Experimental Nephrology.
[76] Mark I McCarthy,et al. Genomics, type 2 diabetes, and obesity. , 2010, The New England journal of medicine.
[77] R. Bilous,et al. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[78] P Corvol,et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.
[79] K. Yamauchi,et al. Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. , 2013, Endocrine journal.
[80] Herbert F. Jelinek,et al. Complexity of heart rate variability in type 2 diabetes - effect of hyperglycemia , 2013, 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).
[81] W. Hörl,et al. A preceding exchange with polyglucose versus glucose solution modifies peritoneal equilibration test results. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[82] G. Murray,et al. Association of apolipoprotein E polymorphism with outcome after head injury , 1997, The Lancet.
[83] O. Dekkers,et al. Genetic associations in diabetic nephropathy: a meta-analysis , 2010, Diabetologia.
[84] J. Jenkins. Ethical implications of genetic information. , 2001, Online journal of issues in nursing.
[85] S. Morris,et al. Diabetic nephropathy is resistant to oral L-arginine or L-citrulline supplementation. , 2014, American journal of physiology. Renal physiology.
[86] Raymond Vanholder,et al. Normal and pathologic concentrations of uremic toxins. , 2012, Journal of the American Society of Nephrology : JASN.
[87] A. Tuttolomondo,et al. O R I G I N a L I N V E S T I G a T I O N Open Access , 2022 .
[88] G. Arsos,et al. Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. , 2006, Journal of diabetes and its complications.
[89] A. Vinik,et al. Diabetic neuropathies. , 2004, The Medical clinics of North America.
[90] A. Bhansali,et al. Endothelial Nitric Oxide Synthase Gene Polymorphism and the Risk of Diabetic Neuropathy in Asian Indian Patients with Type 2 Diabetes , 2013 .
[91] C. Bolton. Peripheral Neurophathies Associated With Chronic Renal Failure , 1980, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[92] K. Santos,et al. The presence of allele D of angiotensin‐converting enzyme polymorphism is associated with diabetic nephropathy in patients with less than 10 years duration of Type 2 diabetes , 2005, Diabetic Medicine.
[93] M. Klinger,et al. The effect of high-tone external muscle stimulation on symptoms and electrophysiological parameters of uremic peripheral neuropathy. , 2012, Clinical nephrology.
[94] S. Rich,et al. Urinary albumin excretion in families with type 2 diabetes is heritable and genetically correlated to blood pressure. , 2000, Kidney international.
[95] Herbert F. Jelinek,et al. Association of cardiovascular risk using non-linear heart rate variability measures with the framingham risk score in a rural population , 2013, Front. Physiol..
[96] Pin-Lan Li,et al. Mechanisms of Homocysteine-Induced Glomerular Injury and Sclerosis , 2007, American Journal of Nephrology.
[97] Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. , 2002, Seminars in cell & developmental biology.
[98] L. Niskanen,et al. Aldose reductase gene polymorphisms and susceptibility to microvascular complications in Type 2 diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[99] F. Najafi,et al. Synergistic effects of the MTHFR C677T and A1298C polymorphisms on the increased risk of micro- and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus. , 2010, Clinical biochemistry.
[100] Yusuke Nakamura,et al. Combinational effect of genes for the renin–angiotensin system in conferring susceptibility to diabetic nephropathy , 2006, Journal of Human Genetics.
[101] I. Strokov,et al. The 262T>C promoter polymorphism of the catalase gene is associated with diabetic neuropathy in type 1 diabetic Russian patients. , 2006, Diabetes & metabolism.
[102] K. Yamada,et al. Association of an (A–C)n dinucleotide repeat polymorphic marker at the 5′‐region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[103] J. Alroy,et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy , 2000, Nature Medicine.
[104] E. Zintzaras,et al. A field synopsis and meta-analysis of genetic association studies in peripheral arterial disease: The CUMAGAS-PAD database. , 2009, American journal of epidemiology.
[105] Kate E Schemmel,et al. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. , 2010, Journal of diabetes and its complications.
[106] V. Nielsen. RECOVERY FROM PERIPHERAL NEUROPATHY AFTER RENAL TRANSPLANTATION , 1970, Acta neurologica Scandinavica.
[107] F. Likis. Folic Acid. , 2016, Journal of midwifery & women's health.
[108] Jeffrey A. Cohen,et al. Increasing homocysteine levels and diabetic autonomic neuropathy , 2001, Autonomic Neuroscience.
[109] T. Motawi,et al. Alterations in circulating angiogenic and anti‐angiogenic factors in type 2 diabetic patients with neuropathy , 2014, Cell biochemistry and function.
[110] N. Tong,et al. Angiotensin-converting enzyme I/D polymorphism and diabetic peripheral neuropathy in type 2 diabetes mellitus: A meta-analysis , 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[111] G. Novelli,et al. TCF7L2 gene polymorphisms and type 2 diabetes: association with diabetic retinopathy and cardiovascular autonomic neuropathy , 2013, Acta Diabetologica.
[112] S. Hampson. Randomised, placebo-controlled trial , 2002 .
[113] R M Heethaar,et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. , 2001, Diabetes care.
[114] P. Berlit,et al. Neurologic complications of acute and chronic renal disease. , 2014, Handbook of clinical neurology.
[115] K. Santos,et al. The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes. , 2005, Diabetes.
[116] Chih-Hsing Wu,et al. Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. , 2007, The Journal of clinical endocrinology and metabolism.
[117] T. Hansen,et al. A Single Nucleotide Polymorphism within the Acetyl-Coenzyme A Carboxylase Beta Gene Is Associated with Proteinuria in Patients with Type 2 Diabetes , 2010, PLoS genetics.
[118] T. Hansen,et al. Polymorphisms in the 3′ UTR in the neurocalcin δ gene affect mRNA stability, and confer susceptibility to diabetic nephropathy , 2007, Human Genetics.
[119] P. Valensi,et al. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications--the French multicenter study. , 2003, Metabolism: clinical and experimental.
[120] Yusuke Nakamura,et al. Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. , 2003, Diabetes.
[121] R. Kawamori,et al. Chemotactic cytokine receptor 5 (CCR5) gene promoter polymorphism (59029A/G) is associated with diabetic nephropathy in Japanese patients with type 2 diabetes: a 10-year longitudinal study. , 2006, Diabetes research and clinical practice.
[122] Jiayan Huang,et al. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). , 2014, JAMA ophthalmology.
[123] Jasmin Divers,et al. A genome-wide association study for diabetic nephropathy genes in African Americans. , 2011, Kidney international.
[124] S. Maeda. Genome-wide search for susceptibility gene to diabetic nephropathy by gene-based SNP. , 2004, Diabetes research and clinical practice.
[125] I. Fermo,et al. The Role of Vitamin B12 in Fasting Hyperhomocysteinemia and Its Interaction with the Homozygous C677T Mutation of the Methylenetetrahydrofolate Reductase (MTHFR) Gene , 2000, Thrombosis and Haemostasis.
[126] S. Janković,et al. An inverse correlation between TNF alpha serum levels and heart rate variability in patients with heart failure. , 2013, Journal of cardiology.
[127] H. Jelinek,et al. Angiotensin-converting enzyme gene DD genotype is associated with increased systolic blood pressure in an Australian Rural Type 2 Diabetic Cohort , 2013, Hypertension Research.
[128] A. Donker,et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial , 2010, BMJ : British Medical Journal.
[129] P. Donnan,et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study , 2008, Pharmacogenetics and genomics.
[130] Saurabh Sharma,et al. Potential role of nitric oxide synthase isoforms in pathophysiology of neuropathic pain , 2014, Inflammopharmacology.
[131] A. Vinik,et al. Diabetic Cardiovascular Autonomic Nerve Dysfunction , 2007 .
[132] A. Vinik,et al. Neuropathy: The Crystal Ball for Cardiovascular Disease? , 2010, Diabetes Care.
[133] J. Townend,et al. The angiotensin-converting enzyme gene I/D polymorphism and heart rate variability following acute myocardial infarction , 2002, Clinical Autonomic Research.
[134] Erdem Buyukbingol,et al. Recent studies of aldose reductase enzyme inhibition for diabetic complications. , 2003, Current medicinal chemistry.
[135] M. Matsuda,et al. Effect of apolipoprotein E4 allele on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients. , 2004, Diabetes care.
[136] M. Cooper. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. , 2004, American journal of hypertension.
[137] W. Berger,et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. , 2011, Investigative ophthalmology & visual science.
[138] H. Sone,et al. Vascular risk factors and diabetic neuropathy. , 2005, The New England journal of medicine.
[139] H. Superko,et al. Statins personalized. , 2012, The Medical clinics of North America.
[140] B. Glaser,et al. Predicting Diabetic Nephropathy Using a Multifactorial Genetic Model , 2011, PloS one.
[141] P. Vokonas,et al. Cardiac Autonomic Dysfunction: Effects From Particulate Air Pollution and Protection by Dietary Methyl Nutrients and Metabolic Polymorphisms , 2008, Circulation.
[142] P. Kempler,et al. Diabetic neuropathy: new strategies for treatment , 2007, Diabetes, obesity & metabolism.
[143] F. Q. Ribeiro. The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.
[144] J. Morgenlander,et al. Peripheral neuropathy in patients with chronic renal failure. A treatable source of discomfort and disability. , 1997, Postgraduate medicine.
[145] Guoliang Huang,et al. MTHFR 677T variant contributes to diabetic nephropathy risk in Caucasian individuals with type 2 diabetes: a meta-analysis. , 2013, Metabolism: clinical and experimental.
[146] Gangyi Yang,et al. Efficacy and Safety of Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiovascular Autonomic Neuropathy: Systematic Review and Meta-Analysis , 2014, PloS one.
[147] A Voss,et al. Angiotensin-converting enzyme and angiotensinogen gene polymorphisms and heart rate variability in twins. , 1998, The American journal of cardiology.
[148] S. Humphries,et al. Association between the rs1050450 glutathione peroxidase-1 (C > T) gene variant and peripheral neuropathy in two independent samples of subjects with diabetes mellitus. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[149] K. Suszták,et al. Transcriptome Analysis of Human Diabetic Kidney Disease , 2011, Diabetes.
[150] Felix Eichinger,et al. Modular Activation of Nuclear Factor-κB Transcriptional Programs in Human Diabetic Nephropathy , 2006, Diabetes.
[151] Toshiko Tanaka,et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. , 2009, American journal of human genetics.
[152] P. Lanting,et al. Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor , 2004, Journal of Neurology.
[153] P. Deyn,et al. Neurological complications in renal failure: a review , 2004, Clinical Neurology and Neurosurgery.
[154] L. Niskanen,et al. Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes. , 2004, Diabetes care.
[155] R. Mahley,et al. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.
[156] D. Wright,et al. Inflammatory Mediators in Diabetic Neuropathy , 2012 .
[157] Z. Rahimi,et al. eNOS 4a/b Polymorphism and Its Interaction with eNOS G894T Variants in Type 2 Diabetes Mellitus: Modifying the Risk of Diabetic Nephropathy , 2013, Disease markers.
[158] J. Melvin,et al. Neuropathy in end-stage renal disease secondary to primary renal disease and diabetes. , 1984, Archives of physical medicine and rehabilitation.
[159] John V Pearson,et al. Identification of PVT1 as a Candidate Gene for End-Stage Renal Disease in Type 2 Diabetes Using a Pooling-Based Genome-Wide Single Nucleotide Polymorphism Association Study , 2007, Diabetes.
[160] D. Santoro,et al. Autonomic dysfunction in uremia. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[161] A. Izenberg,et al. Diabetic Neuropathies , 2015, Seminars in Neurology.
[162] T. Benstead,et al. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. , 2007, The Cochrane database of systematic reviews.
[163] K. Isshiki,et al. Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. , 2001, Kidney international.
[164] V. Lánská,et al. Impact of variants within seven candidate genes on statin treatment efficacy. , 2011, Physiological research.
[165] M. Kiernan,et al. Uremic neuropathy: Clinical features and new pathophysiological insights , 2007, Muscle & nerve.
[166] M. Brownlee. Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.
[167] G. Lundborg,et al. Vascular Endothelial Growth Factor Has Neurotrophic Activity and Stimulates Axonal Outgrowth, Enhancing Cell Survival and Schwann Cell Proliferation in the Peripheral Nervous System , 1999, The Journal of Neuroscience.
[168] C. Colton,et al. An Apolipoprotein E-Mimetic Stimulates Axonal Regeneration and Remyelination after Peripheral Nerve Injury , 2010, Journal of Pharmacology and Experimental Therapeutics.
[169] M. B. Brown,et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. , 1988, The New England journal of medicine.
[170] R. Bedlack,et al. Apolipoprotein E and neuromuscular disease: a critical review of the literature. , 2000, Archives of neurology.
[171] N. Katsilambros,et al. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. , 2011, Journal of diabetes and its complications.
[172] A. Toscano,et al. Uremic vagal neuropathy: has parathyroid hormone a pathogenetic role? , 1986, Functional neurology.
[173] Rayaz A. Malik,et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments , 2010, Diabetes Care.
[174] D. Gaudet,et al. The potential applications of Apolipoprotein E in personalized medicine , 2014, Front. Aging Neurosci..
[175] A. Liberati,et al. A Meta‐analysis of Trials on Aldose Reductase Inhibitors in Diabetic Peripheral Neuropathy , 1996, Diabetic medicine : a journal of the British Diabetic Association.
[176] B. Larijani,et al. Endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism association with type 2 diabetes and its chronic complications. , 2011, Diabetes research and clinical practice.
[177] J. Kessler. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy , 2009, Annals of neurology.
[178] Andrew Stranieri,et al. An approach for Ewing test selection to support the clinical assessment of cardiac autonomic neuropathy , 2013, Artif. Intell. Medicine.
[179] K. Thangaraj,et al. Novel mutations in ATPase 8, ND1 and ND5 genes associated with peripheral neuropathy of diabetes. , 2014, Diabetes research and clinical practice.
[180] A. Demaine,et al. Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene , 1998, Journal of neurology, neurosurgery, and psychiatry.
[181] K. Arimura,et al. Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage , 2009, Diabetic medicine : a journal of the British Diabetic Association.
[182] R. Guymer,et al. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. , 2013, Ophthalmology.
[183] Rania Naguib Abdel Mouteleb Abdel Reheem,et al. Serum vitamin D and parathormone (PTH) concentrations as predictors of the development and severity of diabetic retinopathy , 2013 .
[184] K. Kuboki,et al. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. , 2001, Journal of diabetes and its complications.
[185] Herbert F. Jelinek,et al. Using renyi entropy to detect early cardiac autonomic neuropathy , 2013, 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).
[186] Q. Mansoor,et al. Angiotensin‐converting enzyme (ACE) gene II genotype protects against the development of diabetic peripheral neuropathy in type 2 diabetes mellitus , 2012, Journal of diabetes.
[187] B. Isermann,et al. Asp299Gly and Thr399Ile genotypes of the TLR4 gene are associated with a reduced prevalence of diabetic neuropathy in patients with type 2 diabetes. , 2004, Diabetes care.
[188] T. Tanimoto,et al. Correlation between erythrocyte aldose reductase level and human diabetic retinopathy , 2002, The British journal of ophthalmology.
[189] H. Gerstein. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO‐HOPE , 2002, Diabetes/metabolism research and reviews.
[190] J. Halter,et al. Autonomic Neural Dysfunction in Recently Diagnosed Diabetic Subjects , 1984, Diabetes Care.
[191] D. Soni,et al. Plasma Homocysteine level and its clinical correlation with type 2 diabetes mellitus and its complications , 2014, International Journal of Diabetes in Developing Countries.
[192] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[193] D. Fan,et al. Angiogenin gene polymorphism: A risk factor for diabetic peripheral neuropathy in the northern Chinese Han population , 2013, Neural regeneration research.
[194] A. Hung,et al. An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease , 2006, Human Genetics.
[195] H. Parving,et al. Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy? , 2006, Kidney international.
[196] Xilin Yang,et al. Aldose Reductase Genotypes and Cardiorenal Complications , 2008, Diabetes Care.
[197] T. Moritani,et al. T393C polymorphism of GNAS1 associated with the autonomic nervous system in young, healthy Japanese subjects , 2004, Clinical and experimental pharmacology & physiology.
[198] H. Lidov,et al. Rapid reversal of uremic neuropathy following renal transplantation in an adolescent , 2012, Pediatric Transplantation.
[199] M. Lenhard,et al. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. , 2005, The Journal of clinical endocrinology and metabolism.
[200] C. Mathews,et al. Role of SREBP-1 in the Development of Parasympathetic Dysfunction in the Hearts of Type 1 Diabetic Akita Mice , 2009, Circulation research.
[201] E. G. Erdös,et al. Angiotensin I converting enzyme. , 1975, Circulation research.
[202] M. John,et al. Association between diabetic nephropathy and other diabetic microvascular and macrovascular complications. , 2008, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.
[203] N. Olivarius,et al. Amputations and foot ulcers in patients newly diagnosed with Type 2 diabetes mellitus and observed for 19 years. The role of age, gender and co‐morbidity , 2013, Diabetic medicine : a journal of the British Diabetic Association.
[204] M. Bartelink,et al. Foot ulceration and lower limb amputation in type 2 diabetic patients in dutch primary health care. , 2002, Diabetes care.
[205] B. Canaud,et al. Beta2-microglobulin, a uremic toxin with a double meaning. , 2006, Kidney international.
[206] E. Kobyliansky,et al. Heritability of circulating growth factors involved in the angiogenesis in healthy human population. , 2004, Cytokine.
[207] A. Demaine,et al. Functional differences between the susceptibility Z-2/C-106 and protective Z+2/T-106 promoter region polymorphisms of the aldose reductase gene may account for the association with diabetic microvascular complications. , 2003, Biochimica et biophysica acta.
[208] R. Freeman,et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management , 2011, Diabetes/metabolism research and reviews.
[209] Yu Zhang,et al. Association between MTHFR A1298C polymorphism and neural tube defect susceptibility: a metaanalysis. , 2012, American journal of obstetrics and gynecology.
[210] J. Mega,et al. Identification of Genetic Variants Associated With Response to Statin Therapy , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[211] F. Boomsma,et al. NT-pro-BNP during hypoglycemia and hypoxemia in normal subjects: impact of renin-angiotensin system activity. , 2008, Journal of applied physiology.
[212] M. Craig,et al. Decline in Neurophysiological Function After 7 Years in an Adolescent Diabetic Cohort and the Role of Aldose Reductase Gene Polymorphisms A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. , 2006, Diabetes Care.
[213] S. Chung,et al. Genetic analysis of aldose reductase in diabetic complications. , 2003, Current medicinal chemistry.
[214] Yusuke Nakamura,et al. A Single Nucleotide Polymorphism in KCNQ1 Is Associated With Susceptibility to Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes , 2010, Diabetes Care.
[215] Rodica Pop-Busui,et al. Cardiac Autonomic Neuropathy in Diabetes , 2010, Diabetes Care.
[216] J. Gross,et al. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. , 2003, Diabetes.
[217] A. Tuttolomondo,et al. Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot. , 2008, Metabolism: clinical and experimental.
[218] R. Kawamori,et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy , 2012, Diabetic medicine : a journal of the British Diabetic Association.
[219] Shaughnessy Sl,et al. A 'clinical perspective'. , 1977, Group practice.
[220] Is the C677T polymorphism in methylenetetrahydrofolate reductase gene or plasma homocysteine a risk factor for diabetic peripheral neuropathy in Chinese individuals?☆ , 2012, Neural regeneration research.
[221] T. Moritani,et al. Association of beta-adrenoceptor polymorphisms with cardiac autonomic modulation in Japanese males. , 2007, American heart journal.
[222] D. Feinfeld,et al. Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia. , 1978, The New England journal of medicine.
[223] I. Nishio,et al. [Angiotensin I converting enzyme]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.
[224] C. Eccleston,et al. Systematic review and meta-analysis of psychological therapies for children with chronic pain. , 2014, Journal of pediatric psychology.
[225] J. Baluarte. Neurological Complications of Renal Disease. , 2017, Seminars in pediatric neurology.
[226] S. Dixit,et al. Diabetic peripheral neuropathy and its evaluation in a clinical scenario: a review. , 2014, Journal of postgraduate medicine.
[227] Yusuke Nakamura,et al. Association between single nucleotide polymorphisms within genes encoding sirtuin families and diabetic nephropathy in Japanese subjects with type 2 diabetes , 2011, Clinical and Experimental Nephrology.
[228] Dan Ziegler,et al. Diabetic neuropathies: a statement by the American Diabetes Association. , 2005, Diabetes care.
[229] E. Maltezos,et al. APOE gene polymorphisms and diabetic peripheral neuropathy , 2012, Archives of medical science : AMS.
[230] E. Feldman,et al. The role of growth factors in diabetic peripheral neuropathy , 2004, Journal of the peripheral nervous system : JPNS.
[231] A. Krolewski,et al. The genetic risk of kidney disease in type 2 diabetes. , 2013, The Medical clinics of North America.
[232] A. Hoke,et al. APOE ε4 is not a susceptibility gene in idiopathic or diabetic sensory neuropathy , 2005, Neurology.
[233] Marimuthu Palaniswami,et al. Association of cardiac autonomic neuropathy with alteration of sympatho-vagal balance through heart rate variability analysis. , 2010, Medical engineering & physics.
[234] J. Steimle,et al. L-Arginine Supplementation in Type II Diabetic Rats Preserves Renal Function and Improves Insulin Sensitivity by Altering the Nitric Oxide Pathway , 2014, International journal of endocrinology.
[235] W. Młynarski,et al. Circadian blood pressure variation in normotensive type 2 diabetes patients and angiotensin converting enzyme polymorphism. , 2008, Diabetes research and clinical practice.
[236] H. Aggarwal,et al. Evaluation of spectrum of peripheral neuropathy in predialysis patients with chronic kidney disease , 2013, Renal failure.
[237] H. Boudoulas,et al. Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy. , 1998, Acta cardiologica.
[238] R. Holder,et al. The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[239] J. Lunceford,et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. , 2008, Journal of the American Society of Nephrology : JASN.
[240] V. Kolla,et al. Association of tumor necrosis factor alpha, interferon gamma and interleukin 10 gene polymorphisms with peripheral neuropathy in South Indian patients with type 2 diabetes. , 2009, Cytokine.
[241] S. Jordan. Complement fixing donor‐specific antibodies and allograft loss , 2012, Pediatric transplantation.
[242] C. Guja,et al. Role of Nitric Oxide Synthase Family in Diabetic Neuropathy , 2012 .
[243] C. Jung,et al. Association of serum adipocytokine levels with cardiac autonomic neuropathy in type 2 diabetic patients , 2012, Cardiovascular Diabetology.
[244] S. Visvikis-Siest,et al. Heritability for Plasma VEGF Concentration in the Stanislas Family Study , 2007, Annals of human genetics.
[245] K. Santos,et al. Relationship of p22phox C242T polymorphism with nephropathy in type 2 diabetic patients. , 2005, Journal of nephrology.
[246] H. Prydz. A New Paradigm for Blood Coagulation Research , 2000, Thrombosis and Haemostasis.
[247] T. Murano,et al. [The examination of apoE phenotypes in diabetic patients with peripheral neuropathy]. , 1998, Rinsho byori. The Japanese journal of clinical pathology.
[248] B. J. Klevering,et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. , 2012, Ophthalmology.
[249] Z. Rahimi. ACE insertion/deletion (I/D) polymorphism and diabetic nephropathy. , 2012, Journal of nephropathology.
[250] S. Ha. ACE Insertion/Deletion Polymorphism and Diabetic Nephropathy: Clinical Implications of Genetic Information , 2014, Journal of diabetes research.
[251] E. Brennan,et al. The Genetics of Diabetic Nephropathy , 2013, Genes.
[252] Z. Massy,et al. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. , 2012, Kidney international.
[253] N. Cao,et al. VEGF Genetic Polymorphisms May Contribute to the Risk of Diabetic Nephropathy in Patients with Diabetes Mellitus: A Meta-Analysis , 2014, TheScientificWorldJournal.
[254] Ambady Ramachandran,et al. High prevalence and early onset of cardiac autonomic neuropathy among South Indian type 2 diabetic patients with nephropathy. , 2000, Diabetes research and clinical practice.
[255] M. Laakso,et al. Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus. , 1993, Atherosclerosis.
[256] Robert C. Wolpert,et al. A Review of the , 1985 .
[257] N. Hamajima,et al. Aldose reductase gene is associated with diabetic macroangiopathy in Japanese Type 2 diabetic patients , 2006, Diabetic medicine : a journal of the British Diabetic Association.
[258] I. Degirmenci,et al. Frequency of angiotensin‐converting enzyme gene polymorphism in Turkish type 2 diabetic patients , 2005, International journal of clinical practice.
[259] K. Nanjo,et al. Uncoupling protein 2 promoter polymorphism -866G/A affects peripheral nerve dysfunction in Japanese type 2 diabetic patients. , 2006, Diabetes care.
[260] D. Selvarajah,et al. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy , 2012, Diabetes/metabolism research and reviews.
[261] A. Saunders,et al. APOE genotype is a risk factor for neuropathy severity in diabetic patients , 2003, Neurology.
[262] F. Santilli,et al. CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. , 2009, Journal of atherosclerosis and thrombosis.
[263] M. Černá,et al. Polymorphisms in the Vitamin D Receptor Gene and Parathyroid Hormone Gene in the Development and Progression of Diabetes Mellitus and its Chronic Complications, Diabetic Nephropathy and Non-Diabetic Renal Disease , 2012, Kidney and Blood Pressure Research.
[264] P. Magnusson,et al. Genetic Influences on Peripheral Arterial Disease in a Twin Population , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[265] Jing Zhang,et al. Association study of angiotensin converting enzyme gene polymorphism with elderly diabetic hypertension and lipids levels , 2013, Lipids in Health and Disease.
[266] S. Voidăzan,et al. Cardiovascular Autonomic Neuropathy in Context of Other Complications of Type 2 Diabetes Mellitus , 2013, BioMed research international.
[267] Ryuzo Kawamori,et al. RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. , 2003, Diabetes care.
[268] A. Tahrani,et al. Cardiac autonomic neuropathy in patients with diabetes mellitus. , 2014, World journal of diabetes.
[269] K. Santos,et al. Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis , 2014, BMC Medical Genetics.
[270] A. de Leiva,et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? , 1998, Diabetologia.
[271] R. Ribchester,et al. ApoE isoform-specific regulation of regeneration in the peripheral nervous system. , 2011, Human molecular genetics.
[272] G. Remuzzi,et al. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[273] Jemal H. Abawajy,et al. Enhancing Predictive Accuracy of Cardiac Autonomic Neuropathy Using Blood Biochemistry Features and Iterative Multitier Ensembles , 2016, IEEE Journal of Biomedical and Health Informatics.
[274] Yusuke Nakamura,et al. Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. , 2005, Diabetes.
[275] E. Elstner,et al. Homocysteine-Induced Oxidative Damage: Mechanisms and Possible Roles in Neurodegenerative and Atherogenic Processes , 1995, Zeitschrift fur Naturforschung. C, Journal of biosciences.
[276] E. Benjamin,et al. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function. , 2009, European heart journal.
[277] S. Yadav. Glycemic control in diabetic kidney disease patients , 2012 .
[278] M. Kuehl,et al. Cardiovascular autonomic neuropathies as complications of diabetes mellitus , 2012, Nature Reviews Endocrinology.
[279] M. H. Imam,et al. Pulse wave analysis using tone-entropy algorithm in people with and without foot complaints in a rural diabetes screening clinic , 2010 .
[280] M. El-Bradey,et al. Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular oedema and its correlation with anti‐vascular endothelial growth factor treatment outcomes , 2014, Clinical & experimental ophthalmology.
[281] Soujatya Dhar,et al. Polymorphism of ACE gene as the genetic predisposition of coronary artery disease in Eastern India. , 2012, Indian heart journal.
[282] W. Schady,et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial , 1998, The Lancet.
[283] A. Krolewski,et al. An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients. , 2008, Kidney international.
[284] J. Egido,et al. Potential Role of Nuclear Factor κB in Diabetic Cardiomyopathy , 2011, Mediators of inflammation.
[285] S. Yagihashi,et al. Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients , 2001, Virchows Archiv.
[286] B. Cronstein,et al. Metaanalysis of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms Affecting Methotrexate Toxicity , 2009, The Journal of Rheumatology.
[287] T. Erbas,et al. Thermolabile methylenetetrahydrofolate reductase enzyme genotype is frequent in type 2 diabetic patients with normal fasting homocysteine levels , 2005, Journal of internal medicine.
[288] Y. Wettergren,et al. Gene polymorphisms MTHFRC677T and MTRA2756G as predictive factors in adjuvant chemotherapy for stage III colorectal cancer. , 2011, Anticancer research.
[289] C. Johnston. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. , 1994, Hypertension.
[290] J. Arezzo,et al. Diabetic somatic neuropathies. , 2004, Diabetes care.
[291] W. Almawi,et al. Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786T>C gene variants with diabetic nephropathy. , 2008, Journal of diabetes and its complications.
[292] A. Tuttolomondo,et al. Single nucleotide polymorphisms (SNPs) of pro-inflammatory/anti-inflammatory and thrombotic/fibrinolytic genes in patients with acute ischemic stroke in relation to TOAST subtype. , 2012, Cytokine.
[293] E. Vasquez,et al. Cardiovascular Autonomic Imbalance and Baroreflex Dysfunction in the Apolipoprotein E-deficient Mouse , 2012, Cellular Physiology and Biochemistry.
[294] A. Cox,et al. Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus , 2001, Diabetic medicine : a journal of the British Diabetic Association.
[295] M. Mittlböck,et al. Influence of Methylenetetrahydrofolate Reductase Gene Polymorphisms on Homocysteine Concentrations after Nitrous Oxide Anesthesia , 2008, Anesthesiology.
[296] R. Lattanzio,et al. The Therapeutic Potential of VEGF Inhibition in Diabetic Microvascular Complications , 2007, American journal of cardiovascular drugs : drugs, devices, and other interventions.